title: HLA-DR3 transgenic mice immunized with adenovirus encoding the thyrotropin receptor: T cell epitopes and functional analysis of the CD40 Graves' polymorphism.
abstract: The major histocompatibility (MHC) molecule HLA-DR3 is a susceptibility gene for Graves' disease (GD) in Caucasians. Mice lacking murine MHC and expressing human HLA-DR3 develop thyrotropin receptor (TSHR) antibodies and sometimes hyperthyroidism after vaccination with TSHR-DNA. MHC molecules present peptides processed from antigens to T cells. Therefore, we used DR3-transgenic mice to investigate recognition of TSHR ectodomain peptides. After immunization with TSHR A-subunit adenovirus (A-subunit-Ad) but not control-adenovirus (Control-Ad), splenocytes from DR3 mice responded to A-subunit protein in culture by producing interferon-gamma (IFN-gamma). When challenged with 29 overlapping TSHR peptides, splenocytes from A-subunit-Ad- or Control-Ad-immunized mice responded to several peptides. However, in splenocytes from A-subunit-Ad but not Control-Ad mice, a peptide containing TSHR residues 142-161 induced significantly more IFN-gamma than the same splenocytes in medium alone. Immunized DR3 mice also permitted testing the TSHR-specific function of the CD40 single nucleotide polymorphism (C vs. T) associated with GD. Of three human DR3 human Epstein-Barr virus lines (EBVL), two had C in both alleles (CC) and one was CT. However, these EBVL presented peptides poorly and there was no difference between CC vs. CT EBVL in peptide presentation to splenocytes from immunized mice. A peptide corresponding to residues 145-163 is one of seven suggested to be important in GD based on HLA-binding affinities, T-epitope algorithms, and human studies. Consequently, as in human GD, TSHR amino acids 142-161 appear to include a major T cell epitope in HLA-DR3 transgenic mice immunized with A-subunit-Ad.
authors.affiliation: Autoimmune Disease Unit, Cedars-Sinai Research Institute and UCLA School of Medicine, Los Angeles, California, USA.
authors.forename: Pavel
authors.initials: P
authors.lastname: Pichurin
authors.forename: Nancy
authors.initials: N
authors.lastname: Pham
authors.forename: Chella S
authors.initials: CS
authors.lastname: David
authors.forename: Basil
authors.initials: B
authors.lastname: Rapoport
authors.forename: Sandra M
authors.initials: SM
authors.lastname: McLachlan
mesh_terms: D000256:Adenoviridae; D000595:Amino Acid Sequence; D000818:Animals; D019013:CD40 Antigens / Q000235:genetics*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006111:Graves Disease / Q000235:genetics* / Q000276:immunology*; D015803:HLA-DR3 Antigen / Q000235:genetics* / Q000276:immunology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000276:immunology; D011110:Polymorphism, Genetic; D011989:Receptors, Thyrotropin / Q000235:genetics* / Q000276:immunology; D013972:Thyrotropin / Q000037:antagonists & inhibitors
chemical_list: D019013:CD40 Antigens; D018984:Epitopes, T-Lymphocyte; D015803:HLA-DR3 Antigen; D010446:Peptide Fragments; D011989:Receptors, Thyrotropin; D013972:Thyrotropin